WARSAW, Ind., Aug. 10, 2016 /PRNewswire/ -- Zimmer Biomet
Holdings, Inc. (NYSE and SIX: ZBH) today announced the pricing of
the previously announced underwritten secondary offering of
7,440,675 shares of its common stock by certain of its
stockholders, consisting of affiliates of KKR and TPG. The
shares are being sold to the public at an initial price of
$129.75 per share. The selling
stockholders will receive all of the proceeds of the offering.
Neither Zimmer Biomet nor any of its directors, officers or
other stockholders is selling any shares of common stock in the
offering. The closing of the offering is expected to occur on
August 12, 2016, subject to the
satisfaction of customary closing conditions.
Goldman, Sachs & Co. and J.P. Morgan are acting as joint
book-running managers and the underwriters for the offering.
Zimmer Biomet has filed a registration statement (including a
base prospectus) with the U.S. Securities and Exchange Commission
(the "SEC") relating to these securities. The offering of
these securities was made only by means of a written prospectus
forming part of the effective registration statement. The
base prospectus and the preliminary prospectus supplement have been
filed with the SEC and are available on the SEC's website at
http://www.sec.gov. A copy of the final prospectus supplement
related to the offering will be filed with the SEC, and may be
obtained, when available, from Goldman, Sachs & Co. by
contacting Goldman, Sachs & Co. at Goldman, Sachs & Co.,
Attn: Prospectus Department, 200 West Street, New York, NY 10282, telephone: (212) 902-1171,
facsimile: 212-902-9316 or by emailing
prospectus-ny@ny.email.gs.com; and J.P. Morgan Securities LLC, c/o
Broadridge Financial Solutions, 1155 Long Island Avenue,
Edgewood, NY 11717, Phone:
866-803-9204.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy any securities, nor will there be
any sale of these securities in any state or jurisdiction in which
such offer, solicitation or sale would be unlawful prior to
registration or qualification under the securities laws of any such
state or jurisdiction.
About Zimmer Biomet
Founded in 1927 and headquartered in Warsaw, Indiana, Zimmer Biomet is a global
leader in musculoskeletal healthcare. Zimmer Biomet designs,
manufactures and markets orthopaedic reconstructive products;
sports medicine, biologics, extremities and trauma products; spine,
bone healing, craniomaxillofacial and thoracic products; dental
implants; and related surgical products.
Zimmer Biomet collaborates with healthcare professionals around
the globe to advance the pace of innovation. Its products and
solutions help treat patients suffering from disorders of, or
injuries to, bones, joints or supporting soft tissues.
Together with healthcare professionals, Zimmer Biomet helps
millions of people live better lives.
Zimmer Biomet has operations in more than 25 countries around
the world and sells products in more than 100 countries.
Cautionary Statement Regarding Forward-Looking
Statements
This communication contains forward-looking statements within
the meaning of the safe harbor provisions of the Private Securities
Litigation Reform Act of 1995 regarding the underwritten secondary
offering of shares of Zimmer Biomet's common stock.
Forward-looking statements may be identified by the use of
forward-looking terms such as "may," "will," "expects," "believes,"
"anticipates," "plans," "estimates," "projects," "assumes,"
"guides," "targets," "forecasts," and "seeks" or the negatives of
such terms or other variations on such terms or comparable
terminology. Such statements are based upon the current
beliefs and expectations of management and are subject to
significant risks and uncertainties that could cause actual
outcomes and results to differ materially. For a list and
description of some of such risks and uncertainties, see Zimmer
Biomet's periodic reports filed with the SEC. These factors
should not be construed as exhaustive and should be read in
conjunction with the other cautionary statements that are included
in Zimmer Biomet's filings with the SEC. Zimmer Biomet
disclaims any intention or obligation to update or revise any
forward-looking statements, whether as a result of new information,
future events or otherwise, except as may be set forth in its
periodic reports. Accordingly, such forward-looking
statements speak only as of the date made. Readers of this
communication are cautioned not to place undue reliance on these
forward-looking statements, since, while management believes the
assumptions on which the forward-looking statements are based are
reasonable, there can be no assurance that these forward-looking
statements will prove to be accurate. This cautionary
statement is applicable to all forward-looking statements contained
in this communication.
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/zimmer-biomet-holdings-announces-pricing-of-secondary-offering-of-common-stock-300311722.html
SOURCE Zimmer Biomet Holdings, Inc.